Please login to the form below
Relypsa
This page shows the latest Relypsa news and features for those working in and with pharma, biotech and healthcare.
Vifor wins European approval for Veltassa
The go-ahead is a significant milestone for Vifor Pharma Group - who acquired Veltassa from Relypsa - as it marks the drug’s first regulatory approval outside the US. ... Relypsa plans to submit Veltassa applications in other markets worldwide and the
Latest news
-
FDA turns down AZ's ZS-9 once again on manufacturing issues
On the plus side for AZ it seems that safety is not causing a concern for the regulator - something that resulted in rival drug Veltassa (patiromer) from Relypsa - now part of
-
Rare disease therapies head the ‘class of 2015’
Relypsa. USA. rolapitant. Varubi. chemotherapy-induced nausea and vomiting (CINV). neurokinin-1 receptor antagonist.
More from news
Approximately 1 fully matching, plus 2 partially matching documents found.
Latest Intelligence
-
Deal Watch July 2016
Veltassa was approved in late 2015 and Relypsa achieved revenues of $30.9m since its launch, making the 50x revenue multiple paid look relatively attractive. ... Licence, co-development, equity stake. 2, 561. Relypsa/ Galenica. Veltassa - Potassium binder
-
Pharma deals in August 2015
Collaboration. 219. Relypsa. Vifor Fresenius. Patiromer oral suspension in treating hyperkalemia.
-
Pharma deals during November 2013
Relypsa, a late-stage biotech developing a phase III treatment for hyperkalemia, get its IPO away but at a significantly reduced price (from a range of $16 to $19 per share
-
Pharma deals during October 2013
Examples of recent IPOS. Company. Product/technology. Target ($m). Relypsa. Patiromer for hyperkalaemia in chronic kidney disease (phase III).
More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.
Latest appointments
-
OPKO appoints vice president of medical affairs
Dr Douglass Laidlaw brings experience from Relypsa and Sanofi. Miami-based OPKO Health has appointed Dr Douglass Laidlaw as vice president of medical affairs. ... He previously served as Relypsa's executive director, medical affairs and Sanofi's national
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
-
Pharmacovigilance Manager
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
-
Pharmacovigilance Project Lead
- Highly competitive salary
-
Technical Sales Representative
- Highly competitive salary
-
Senior Medical Writer
- Highly competitive salary
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
- Novo Nordisk suspended from ABPI over ‘serious’ code of practice breaches
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Results for Astellas’ non-hormonal menopause drug published in The Lancet
- 2023 PM Society Awards – winners announced
- Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray
- Biogen and Eisai’s Alzheimer’s drug to be covered by US Veterans Health Administration
- Quantum Computing, Artificial Intelligence, & Machine Learning for Drug Discovery
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- The increasing value of rare disease trials
- Wrapping up EAU with a Look at Medscape’s Urology Impact
- MHRA to introduce new UK clinical trials framework
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Locus Biosciences announces first patient treated in urinary tract infection trial
- Biogen and Eisai’s Alzheimer’s drug to be covered by US Veterans Health Administration
- Dermavant reports positive phase 3 results for Vtama cream in atopic dermatitis
- Pfizer/BioNTech’s Omicron-adapted booster approved by FDA for young children
- Havas Health & You appoints Alex Okada as chief creative officer of Havas Lynx Group
PMHub
Thrive Agency
We are a specialist health communication agency creating powerful and trusted content. If you’re looking for a partner to help...
Latest intelligence
- Rare diseases: not so rare after all
- The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
- Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
- Register now for part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years....
- DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
- It’s long been the case that pharma lags behind other industries when it comes to digital adoption and engagement. So, what can we learn from these other industries, and how...
